Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nifedipine
Drug ID BADD_D01566
Description Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action.[A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383]
Indications and Usage For the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents).
Marketing Status Prescription; Discontinued
ATC Code C08CA05
DrugBank ID DB01115
KEGG ID D00437
MeSH ID D009543
PubChem ID 4485
TTD Drug ID D04OSE
NDC Product Code 50090-5284; 61919-319; 55289-798; 11014-0036; 70771-1367; 67877-756; 70771-1192; 53808-1118; 50742-261; 24979-010; 52932-0711; 50090-0695; 50742-260; 55289-907; 71335-0497; 68071-3347; 68382-685; 50090-3034; 71610-290; 68682-105; 68071-4411; 71205-965; 62175-261; 61919-192; 0395-8095; 24979-011; 48292-0034; 51927-0233; 63759-7009; 63187-875; 49452-4847; 71205-412; 23155-195; 71335-0744; 59651-296; 62175-262; 72214-503; 12527-8861; 70896-2026; 0228-2497; 68382-688; 71335-1721; 38779-0280; 69315-211; 55154-4690; 46438-0052; 50090-4158; 51927-2311; 0228-2530; 67877-758; 60524-002; 68682-107; 55154-8177; 52133-0028; 50268-598; 59651-297; 0069-2670; 24979-009; 0069-2650; 68084-598; 51407-622; 50090-0697; 51552-0720; 70518-2679; 71610-055; 0904-7082; 68071-4097; 51407-623; 11014-0038; 71052-650; 70771-1190; 60429-047; 68382-687; 72789-219; 49452-4852; 50090-1843; 11014-0341; 70771-1365; 23155-194; 71610-144; 63629-7215; 0904-7080; 68682-109; 71205-964; 60429-163; 68071-2619; 50742-621; 60429-048; 70807-503; 60592-507; 51407-624; 62175-260; 48589-0006; 12527-8841; 68382-690; 68382-686; 12527-0787; 52133-0009; 11014-0342; 79572-025; 50742-262; 62991-1106; 0069-2660; 67877-757; 50090-5328; 68084-603; 50090-4442; 50742-620; 50268-601; 0904-7081; 60429-049; 59762-1004; 68645-513; 12527-8851; 68084-597; 50090-4234; 71335-1550; 69315-212; 68071-4558; 50268-599; 71610-012; 68645-512; 68682-108; 68682-106; 70771-1191; 66267-831; 68981-039; 50742-622; 50090-4249; 46438-0635; 68071-4334; 50268-597; 11014-0035; 71205-963; 60687-425; 59651-295; 68071-4281; 68071-3281; 65427-250; 71335-0489; 68382-689; 70771-1366; 68788-7642; 68788-8164
Synonyms Nifedipine | Bay-1040 | Bay 1040 | Bay1040 | BAY-a-1040 | BAY a 1040 | BAYa1040 | Cordipin | Cordipine | Corinfar | Korinfar | Nifangin | Nifedipine Monohydrochloride | Monohydrochloride, Nifedipine | Procardia | Procardia XL | Nifedipine-GTIS | Nifedipine GTIS | Vascard | Adalat | Fenigidin
Chemical Information
Molecular Formula C17H18N2O6
CAS Registry Number 21829-25-4
SMILES CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionS-adenosylhomocysteine hydrolase-like protein 1O43865Not Available7054240; 6330251; 7059972
Gingival hyperplasiaAndrogen receptorP10275T1121126152187
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.0030.000504%Not Available
Disorientation19.13.01.002; 17.02.05.0150.000504%Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.003363%
Drug hypersensitivity10.01.01.0010.024047%Not Available
Drug withdrawal syndrome neonatal19.07.02.012; 18.04.13.001; 08.06.02.0080.000088%Not Available
Dry mouth07.06.01.002--
Dysaesthesia17.02.06.003--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.001345%
Dyspnoea22.02.01.004; 02.01.03.002--
Dysuria20.02.02.0020.000336%
Eclampsia24.08.07.001; 20.01.08.001; 18.02.03.001; 17.12.03.0120.000504%Not Available
Ectopic pregnancy18.02.02.0020.000336%Not Available
Electrocardiogram ST segment depression13.14.05.0050.000336%Not Available
Electrolyte imbalance14.05.01.0020.000336%Not Available
Eosinophilia01.02.04.001--
Eosinophilic pneumonia01.02.04.003; 22.01.01.0040.000673%Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Erythromelalgia24.03.01.001; 23.06.05.002--Not Available
Extrasystoles02.03.02.003--Not Available
Eye disorder06.08.03.001--Not Available
Eye haemorrhage24.07.05.002; 06.07.02.001--Not Available
Eye pain06.08.03.002--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 14 Pages